Umbralisib Tosylate Patent Expiration
Umbralisib Tosylate is used for treating relapsed or refractory follicular lymphoma (FL) and marginal zone lymphoma (MZL) after multiple prior lines of systemic therapy. It was first introduced by Tg Therapeutics Inc
Umbralisib Tosylate Patents
Given below is the list of patents protecting Umbralisib Tosylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ukoniq | US10414773 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations | May 26, 2035 | Tg Theraps |
| Ukoniq | US10947244 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations | May 26, 2035 | Tg Theraps |
| Ukoniq | US9969740 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations | May 26, 2035 | Tg Theraps |
| Ukoniq | US10072013 | Selective PI3K delta inhibitors | Jul 02, 2033 | Tg Theraps |
| Ukoniq | US10570142 | Selective PI3K delta inhibitors | Jul 02, 2033 | Tg Theraps |
| Ukoniq | US10981919 | Selective PI3K delta inhibitors | Jul 02, 2033 | Tg Theraps |
| Ukoniq | US9150579 | Selective PI3K delta inhibitors | Jul 02, 2033 | Tg Theraps |
| Ukoniq | US9669033 | Selective PI3K delta inhibitors | Jul 02, 2033 | Tg Theraps |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Umbralisib Tosylate's patents.
Latest Legal Activities on Umbralisib Tosylate's Patents
Given below is the list recent legal activities going on the following patents of Umbralisib Tosylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US9669033 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US10570142 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US9150579 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US10072013 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 08 Jan, 2024 | US10570142 |
| Surcharge for late Payment, Small Entity | 08 Jan, 2024 | US10570142 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US10072013 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US10570142 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US9150579 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US9669033 |
Umbralisib Tosylate's Family Patents
